Teva’s migraine drug Ajovy looks set for EU approvalTeva’s migraine drug Ajovy (fremanezumab) has moved closer to the EU market after the influential CHMP regulatory committee Share XTeva’s migraine drug Ajovy looks set for EU approvalhttps://pharmaphorum.com/news/tevas-migraine-drug-ajovy-looks-set-for-eu-approval/
CVS covers migraine drugs from Teva and Lilly, excludes Amgen’s rivalUS pharmacy benefits manager CVS Health Corp has added new migraine drugs from Teva and Eli Lilly to Share XCVS covers migraine drugs from Teva and Lilly, excludes Amgen’s rivalhttps://pharmaphorum.com/news/cvs-covers-migraine-drugs-from-teva-and-lilly-excludes-amgens-rival/
FDA advisers back Amgen/UCB’s osteoporosis drug EvenityAmgen’s bone-building drug Evenity looks on course for US approval in certain women with osteoporosis after a panel Share XFDA advisers back Amgen/UCB’s osteoporosis drug Evenityhttps://pharmaphorum.com/news/fda-advisers-back-amgen-ucbs-osteoporosis-drug-evenity/
Japan approves Amgen’s osteoporosis drugAmgen’s osteoporosis bone-forming drug Evenity (romosozumab) has been approved in Japan, ahead of a crunch review by advisers Share XJapan approves Amgen’s osteoporosis drughttps://pharmaphorum.com/news/japan-approves-amgens-osteoporosis-drug/
Mundipharma’s Neulasta biosimilar approved in EUA second cut-price biosimilar of Amgen’s Neulasta (pegfilgrastim) long-acting white blood cell booster is to hit the EU Share XMundipharma’s Neulasta biosimilar approved in EUhttps://pharmaphorum.com/news/mundipharmas-neulasta-biosimilar-approved-in-eu/
Lilly files new class migraine drug with FDAEli Lilly has filed a new migraine drug, lasmiditan, with the US regulator, the first drug in its Share XLilly files new class migraine drug with FDAhttps://pharmaphorum.com/news/lilly-files-new-class-migraine-drug-with-fda/
Amgen cuts US price of cholesterol drug by 60%Amgen is cutting the US price of its cholesterol drug Repatha by 60%, following a similar decision by Share XAmgen cuts US price of cholesterol drug by 60%https://pharmaphorum.com/news/amgen-cuts-us-price-of-cholesterol-drug-by-60/
Teva slumps after Express Scripts funds migraine rivals in USA major prescription benefit manager in the US will not reimburse Teva’s preventative migraine drug Ajovy (fremanezumab), in Share XTeva slumps after Express Scripts funds migraine rivals in UShttps://pharmaphorum.com/news/teva-slumps-after-express-scripts-funds-migraine-rivals-in-us/
Lilly pushes into migraine market as Emgality approved in USThe FDA has approved Eli Lilly’s Emgality (galcanezumab) for migraine prevention in adults, the third in a group Share XLilly pushes into migraine market as Emgality approved in UShttps://pharmaphorum.com/news/lilly-pushes-into-migraine-market-as-emgality-approved-in-us/
